The inhibition of CSPG4 signaling diminished AKT and ERK activity, reduced tumor-associated inflammation, decreased the transcription of pro-mitogenic early growth response protein 1 (EGR1), and facilitated the execution of pro-apoptotic programs [103]. The gene discussed is CSPG4; the disease is neoplasm.